Loading...

I-Mab

IMABNASDAQ
Healthcare
Biotechnology
$5.16
$0.00(0.00%)

I-Mab (IMAB) Financial Performance & Income Statement Overview

Access detailed quarterly and annual financial reports for I-Mab (IMAB), covering cash flow, earnings, and balance sheets.

Revenue Growth
-100.00%
100.00%
Operating Income Growth
69.63%
69.63%
Net Income Growth
88.93%
88.93%
Operating Cash Flow Growth
27.55%
27.55%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-3.55%
3.55%
ROIC
-22.89%
22.89%

I-Mab (IMAB) Income Statement & Financial Overview

View the income breakdown for I-Mab IMAB across both annual and quarterly reports.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$0.00$0.00$0.00$0.00
Cost of Revenue$0.00$0.00$0.00$0.00
Gross Profit$0.00$0.00$0.00$0.00
Gross Profit Ratio$0.00$0.00$0.00$0.00
R&D Expenses$777000.00$6.03M$4.47M$22.80M
SG&A Expenses$4.49M$7.34M$7.94M$11.87M
Operating Expenses$5.27M$13.37M$12.41M$15.008M
Total Costs & Expenses$5.27M$13.37M$12.41M$15.008M
Interest Income$1.87M$2.20M$2.45M$1.92M
Interest Expense$0.00$0.00$0.00$0.00
Depreciation & Amortization$0.00$0.00$0.00$5.99M
EBITDA-$5.27M-$12.10M-$12.41M-$15.008M
EBITDA Ratio$0.00$0.00$0.00$0.00
Operating Income-$5.27M-$13.37M-$12.41M-$15.008M
Operating Income Ratio$0.00$0.00$0.00$0.00
Other Income/Expenses (Net)$2.12M$2.53M-$8.08M-$34.48M
Income Before Tax-$3.15M-$10.84M-$20.49M-$49.49M
Income Before Tax Ratio$0.00$0.00$0.00$0.00
Income Tax Expense$0.00$0.00$0.00-$42.68M
Net Income-$3.15M-$9.06M-$20.49M$25.13M
Net Income Ratio$0.00$0.00$0.00$0.00
EPS-$0.05-$0.11-$0.25$0.31
Diluted EPS-$0.05-$0.11-$0.25$0.31
Weighted Avg Shares Outstanding$81.60M$81.50M$81.50M$81.78M
Weighted Avg Shares Outstanding (Diluted)$81.60M$81.50M$81.50M$80.93M

The company's financials show resilient growth, with revenue advancing from $0.00 in Q2 2024 to $0.00 in Q1 2025. Gross profit remained healthy with margins at N/A in Q1 2025 compared to N/A in Q2 2024. Operating income hit -$5.27M last quarter, sustaining a consistent N/A margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$5.27M. Net income rose to -$3.15M, while earnings per share reached -$0.05. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;